Pharmaceutical

Gilead and Merus enter trispecific antibody discovery deal

Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.

Mar 7, 2024 - 18:00
Gilead and Merus enter trispecific antibody discovery deal
Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.
Read the original article

Tags:

Previous Article

Merck reports drop in net income for fiscal 2023

Next Article

Clinical trials in Africa: Where there is a challenge, there is an opportunity

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

To protect chickens from bird flu, researchers try to CRISPR in immunity

To protect chickens from bird flu, researchers try to C...

Oct 10, 2023

STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research

STAT+: Maryland pushes first-of-its-kind bill to promot...

Apr 25, 2023

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck buys Mirus Bio to boost viral vector bioprocessin...

Aug 3, 2024